Showing results (1071-1080 of 1,702) with videos related to

Sort By:
Pageof 171
Preventive Medicine|March 31, 2025
Evaluating the predictive performance of different data sources to forecast overdose deaths at the neighborhood level with machine learning in Rhode IslandJohn C Halifax, Bennett Allen, Claire Pratty, et al.
Cancer|December 16, 2011
Clinical outcomes of oncologic gastrointestinal resections in patients with cirrhosisAvo Artinyan, Christy L Marshall, Courtney J Balentine, et al.
American Journal of Preventive Medicine|July 5, 2021
Supervised Injection Facilities as Harm Reduction: A Systematic ReviewTimothy W Levengood, Grace H Yoon, Melissa J Davoust, et al.
AIDS and Behavior|January 22, 2022
Periods of Homelessness Linked to Higher VACS Index Among HIV-Positive People Who Use DrugsHudson Reddon, M Eugenia Socias, Amy Justice, et al.
The Journal of Surgical Research|July 31, 2012
Hand-assisted laparoscopy leads to efficient colorectal cancer surgerySonia T Orcutt, Christy L Marshall, Courtney J Balentine, et al.
Telemedicine Journal and E-Health : the Official Journal of the American Telemedicine Association|May 22, 2014
Implementation of a regional virtual tumor board: a prospective study evaluating feasibility and provider acceptanceChristy L Marshall, Nancy J Petersen, Aanand D Naik, et al.
Drug and Alcohol Dependence|November 1, 2025
Trajectories of neighborhood-level overdose risk predictions for prioritization of harm reduction services: Results from the PROVIDENT studyAlexandra Skinner, William C Goedel, Benjamin D Hallowell, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|July 28, 2010
Nicotinic acetylcholine receptor α1 promotes calpain-1 activation and macrophage inflammation in hypercholesterolemic nephropathyGuoqiang Zhang, Alison L Thomas, Amanda L Marshall, et al.
Atherosclerosis|September 3, 2010
In vivo knockdown of nicotinic acetylcholine receptor α1 diminishes aortic atherosclerosisGuoqiang Zhang, Amanda L Marshall, Alison L Thomas, et al.
Cancer Chemotherapy and Pharmacology|October 10, 2015
Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinomaAndrew Gabrielson, Anteneh A Tesfaye, John L Marshall, et al.
Pageof 171